The FLI8.26 antibody reacts with human CD32 (FcγRII), an ~40 kDa type 1 transmembrane glycoprotein that mediates several functions including phagocytosis, cytotoxicity, immunomodulation, and platelet aggregation. The FLI8.26 antibody cross-reacts with monocytes, granulocytes, and platelets. CD32 is encoded by three genes (A, B, C) and at least 6 isoforms are generated via alternative mRNA splicing, i.e., IIa1, IIa2, IIb1, IIb2, IIb3 and IIc. All isoforms are expressed by monocytes/macrophages, placental trophoblasts, and endothelial cells. In addition, the IIb isoform is expressed by B cells, and the IIa isoform by platelets, granulocytes and, weakly, by B cells. Isoform IIc is expressed by NK cells and neutrophils. Clone FLI8.26 has been verified to bind to FcγRIIa and FcγRIIb, and reportedly binds to FcγRIIc, which shares an identical amino acid sequence to FcγRIIb in the signal peptide, extracellular and transmembrane domains. Clone FLI8.26 inhibits binding of the FcγRIIa-specific clone IV.3 antibody in flow cytometry analyses. CD32 binds weakly to the Fc region of monomeric IgG but more strongly to IgG aggregates and immune complexes. These interactions can result in non-specific labeling in antibody-based detection and cell separation experiments and the FLI8.26 antibody may be used as a blocking antibody to reduce non-specific binding.